URGN Stock Forecast: UroGen Pharma Ltd. Price Predictions for 2026-2027
The 7 Wall Street analysts covering UroGen Pharma Ltd. hold a median 12-month price target of $60 — +117.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 60 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores UroGen Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (97): Sales and profits are climbing, and climbing faster than before.
Accruals (7): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
URGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on URGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +117.0% from it.
Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | Guggenheim | Maintains | Buy | $58 → $56 |
| 19 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $75 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $42 → $58 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $75 |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $50 → $60 |
| 21 July 2026 | Guggenheim | Maintains | Buy | $32 → $42 |
| 16 July 2026 | Oppenheimer | Maintains | Outperformer | $40 → $50 |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 31 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 2 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 5 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 19 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for URGN.
This page is one stock. Monday covers all of them.
URGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
URGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, UroGen Pharma Ltd. returned +11.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
URGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.1×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 18% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 90.9%
- Operating margin
- −12.4%
- Net margin
- —
Higher than 96% of US stocks
Higher than 25% of US stocks
- Return on equity
- —
- Return on assets
- −8.5%
- Dividend yield
- —
Higher than 28% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
UroGen Pharma Ltd. has a market value of $1.6B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $188.7M. The latest quarter grew 199.2% year on year.
Net income over the same four quarters: −$97.6M, a −51.7% net margin.
Diluted earnings per share, trailing twelve months: −$1.98.
Free cash flow in the twelve months to 30 June 2026: −$159.1M.
forward P/E: 12.5× — the forward figure prices analyst consensus estimates, not reported earnings.
UroGen Pharma Ltd. employs 300 people — $629K of revenue per employee.
Data provided by Twelve Data
URGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at URGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own UroGen Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about URGN
What is the URGN stock price forecast for 2026-2027?
The 7 Wall Street analysts covering UroGen Pharma Ltd. have a median 12-month price target of $60, with estimates ranging from $54 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is URGN stock a buy right now?
Of the 7 analysts covering UroGen Pharma Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UroGen Pharma Ltd. 60 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank URGN?
As at 21 Nov 2026, UroGen Pharma Ltd. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).
Will URGN stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +117.0% from the last close, and Ticker Nerd's factor model ranks UroGen Pharma Ltd. 60 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the URGN stock forecast for 2030?
No analyst covering UroGen Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for URGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $54 to $75 over the next 12 months.
How has URGN stock performed over the past year?
UroGen Pharma Ltd. returned +11.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does UroGen Pharma Ltd. do?
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue. Its marketed therapies and pipeline are built around non-surgical, organ-sparing approaches for conditions such as upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances additional investigational candidates aimed at expanding options in uro-oncology, combining drug formulation expertise with targeted delivery technologies. Headquartered in Princeton, New Jersey, with operations in Israel, the company plays a specialized role in the urology and oncology markets by focusing on treatments tailored to diseases of the urinary tract.
CEO Ms. Elizabeth A. Barrett · 300 employees · United States · https://www.urogen.com